Recently, Dr. Tauseef Butt, President and CEO, spoke with Joel Hornby of Cambridge Healthtech Institute. Dr. Butt spoke of the role that small molecules, specifically inhibitors of ubiquitin protease 7 (USP7), play in immune oncology. In addition, Dr. Butt discussed animal model data generated using Progenra’s USP7i compounds, as well as Progenra’s unique Drug Discovery Platform. Dr. Butt will further discuss these topics during Immunomodulatory Small Molecules and Targeting the Ubiquitin Proteasome System at the Discovery on Target conference, September 27-28.
- Progenra receives funding from the Michael J Fox Foundation to develop Parkin activators to treat Parkinson’s disease.
- Progenra Scientists publish a chapter in the ACS 2019 Medicinal Chemistry Reviews.
- Characterization of Selective Covalent inhibitors of USP7- AACR Poster
- Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
- Immune Regulation by Protein Ubiquitination: Roles of the E3 Ligases VHL and Itch